Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04792489 · ClinicalTrials.gov registry record · Phase 2
DALY II USA/ MB-CART2019.1 for DLBCL
A Phase 2 study of Central Nervous System Lymphoma and Mantle Cell Lymphoma (MCL), sponsored by Miltenyi Biomedicine.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 248
- Enrollment target
- 20
- Study locations
NCT04792489: Recruiting Phase 2 study of Central Nervous System Lymphoma and Mantle Cell Lymphoma (MCL), sponsored by Miltenyi Biomedicine.
NCT04792489 is a Phase 2 study of Central Nervous System Lymphoma and Mantle Cell Lymphoma (MCL) that is actively recruiting participants, run by Miltenyi Biomedicine. The registered enrollment target is 248 participants, above the 88-participant average among 14 other Central Nervous System Lymphoma trials with a reported enrollment target (182% higher). The trial reports 20 study locations across 17 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04792489, a Phase 2 study of Central Nervous System Lymphoma and Mantle Cell Lymphoma (MCL), is actively recruiting participants, sponsored by Miltenyi Biomedicine.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 248 participants
- Enrollment target
- 20
- Study locations
Study Summary
DALY II USA is a phase II, multi-center, single arm study to evaluate the efficacy, safety, and pharmacokinetics of zamtocabtagene autoleucel (MB-CART2019.1) in patients with relapsed and/or refractory diffuse large B cell lymphoma (DLBCL) after receiving at least two lines of therapy. Additional cohorts include subjects with B-cell primary or secondary central nervous system (CNS) lymphoma (PCNSL) and (SCNSL), mantle cell lymphoma (MCL) and Richter's transformation (RT) after receiving at least one line of therapy.
Primary Outcome
ORR
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- DRUG Bendamustine
- BIOLOGICAL zamtocabtagene autoleucel (MB-CART2019.1)
Study Locations (20)
Arizona
- Banner MD Anderson Cancer Center - Gilbert
- Mayo Clinic - Phoenix
California
- UC San Diego Health - La Jolla
- Stanford University - Stanford
Georgia
- Winship Cancer Institute of Emory University - Atlanta
- Georgia Cancer Center at Augusta University - Augusta
Connecticut
- Yale University - New Haven
Florida
- Baptist Health Miami Cancer Institute - Miami
Illinois
- Robert H Lurie Cancer Center - Chicago
Kansas
- University of Kansas Cancer Center - Westwood
Maryland
- University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 248 participants |
| Start Date | 2021-05-25 |
| Est. Completion | 2028-12-31 |
| Phase | Phase 2 |
What NCT04792489 shows while recruiting
NCT04792489 is an interventional study that assigns participants to a tested intervention. The registered 248 participants enrollment target is mid-sized for trials with a published cap, above the 88-participant average among 14 other Central Nervous System Lymphoma trials with a reported enrollment target (182% higher).
The record links to 8 conditions, with Central Nervous System Lymphoma appearing as the primary indexed condition, and to 4 interventions - of which Cyclophosphamide is the first listed.
NCT04792489 names 20 study sites across 17 states, led by Arizona, California, Georgia.
Frequently Asked Questions
What is clinical trial NCT04792489 about?
NCT04792489 is a clinical study titled "DALY II USA/ MB-CART2019.1 for DLBCL". DALY II USA is a phase II, multi-center, single arm study to evaluate the efficacy, safety, and pharmacokinetics of zamtocabtagene autoleucel (MB-CART2019.1) in patients with relapsed and/or refractory diffuse large B cell lymphoma (DLBCL) after receiving at least two lines of therapy. Additional co...
What is the current status of trial NCT04792489?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 248 participants. The study started on 2021-05-25. Estimated completion is 2028-12-31.
What conditions does trial NCT04792489 study?
This clinical trial studies the following conditions: Central Nervous System Lymphoma, Mantle Cell Lymphoma (MCL), Relapsed Diffuse Large B-cell Lymphoma, Transformed Lymphoma, High Grade B-cell Lymphoma (HGBCL).
What interventions are being tested in trial NCT04792489?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), Bendamustine (DRUG), zamtocabtagene autoleucel (MB-CART2019.1) (BIOLOGICAL).
Who is sponsoring clinical trial NCT04792489?
This trial is sponsored by Miltenyi Biomedicine, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04792489 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Central Nervous System Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04792489's enrollment target sits among peer trials
248 2nd of 14 the highest of 14 other Central Nervous System Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Central Nervous System Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Pilot Study of Acalabrutinib in Relapsed/Refractory Primary and Secondary CNS Lymphomas
ACTIVE NOT RECRUITING · Phase 2
-
Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS)
ACTIVE NOT RECRUITING · Phase 2
-
Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom
ACTIVE NOT RECRUITING · Phase 2
-
Loncastuximab Tesirine and Rituximab Following Stereotactic Radiosurgery in Patients With Central Nervous System Lymphomas (SOLAR)
RECRUITING · Phase 1
-
CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies
RECRUITING · Phase 1
-
Intracerebroventricular Administration of CD19-CAR T Cells (CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/Mem T-lymphocytes) for the Treatment of Central Nervous System Lymphoma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04577911 · 248 participants
How is Social Connection Represented in the Brain?
- NCT04777994 · 248 participants · Phase 1
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
- NCT04830137 · 248 participants · Phase 1
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
- NCT05398185 · 248 participants · NA
WiseApp for Spanish Speakers Living With HIV
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI